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Conclusions: Experience with the MitraClip in patients with a dilated left ventricle
suggests that the procedure is safe and feasible in most patients. Mortality and heart
failure-related hospital rates are low. This therapy may be an alternative to surgery in this
high-risk group of patients.
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Background: Left ventricle (LV) remodeling after anterior wall myocardial infarction leads
to increased LV volumes, myocardial stress and ultimately congestive heart failure (CHF).
Treatment options are limited for these high morbidity and mortality risk population.
Methods: The study included 39 patients with ischemic CHF class II-IV (NYHA),
akinetic or dyskinetic wall abnormality, ejection fraction between 15 and 40% and no
revascularization options were enrolled in 14 U.S. and European sites. The device was
deployed into the left ventricle apex to partition off the damaged myocardium. Warfarin
and ASA treatment for 1-year post implant. All events were adjudicated and CT, EKG and
echo data were analyzed by independent core labs.
Results: End-diastolic volume was 127.5cc pre-procedure, 106.7cc at 6-month and
114.7cc at 2 years by echo (p0.74 6M vs 2Y). There were no strokes and worsening
CHF or death occurred in 32.9% (per Protocol n34) or 29.5% (treated pts, n31) of
patients at 2 years. Average NYHA class reduced from 2.6 to 1.9 with 87% of patients
reporting improvement in symptoms at 12 months. Adjudication of 3-year clinical events
will be completed in July 2012 and will be available for presentation.
Conclusions: Sustained 2-year improvement in symptoms and LV volume was observed
after PVR using the ParachuteTM device in patients with ischemic CHF and anterior LV
dilatation. Three-year clinical data will provide important insights into long-term safety of
this novel therapy.
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Background: Recent studies have raised major concerns about an increased risk of
cerebrovascular events (CVE) following transcatheter aortic valve implantation (TAVI).
The objective of this study was to evaluate the timing, predictive factors and prognostic
value of CVE following TAVI.
Methods: A total of 1061 consecutive patients who underwent TAVI with a balloon-
(64%) or a self- (36%) expandable valve in 5 centers were included. CVEs were defined
using the VARC criteria and further classified according to timing with respect to the
TAVI procedure as acute (24 hours), subacute (1 to 30 days), and late (30 days). All
baseline, procedural, and follow-up data were prospectively recorded.
Results: CVEs occurred in 54 patients (5.1%; stroke: 4.2%, TIA: 0.9%) within 30 days
following TAVI, and were acute and subacute in 54% and 46% of cases, respectively. The
predictors of acute CVEs were balloon postdilation (BPD) of the valve prosthesis (OR:
2.46, 95% CI: 1.07-5.67) and valve dislodgment/embolization (OR: 4.36, 95% CI:
1.21-15.69); new-onset atrial fibrillation [NOAF] (OR 2.72, 95% CI 1.10-6.73) was the
only predictor of subactute CVEs. Late CVEs occurred in 35 patients (3.6%; stroke: 2.1%,
TIA: 1.5%) at a median follow-up of 12 (3-23) months. The independent predictors of late
CVEs were chronic AF (HR: 2.62, 95% CI 1.34-5.11) and peripheral vascular disease
(HR: 2.07, 95% CI 1.05-4.08). Major stroke was independently associated with 30-day
(OR 7.43, 95% CI 2.45-22.53) and late (HR: 1.75, 95 CI% 1.01-3.03) mortality.
Conclusions: In a large cohort of patients undergoing TAVI, the rate of acute and
subacute CVEs was 2.7% and 2.4%, respectively. While mechanical factors such as
further stretching of the valve prosthesis with BPD and valve embolization were the
predictors of acute CVEs, atrial arrhythmias (NOAF) determined a higher risk for
subacute events. Late events were mainly determined by chronic AF and peripheral
vascular disease. The occurrence of major stroke was associated with an increased early
and late mortality. These results provide important insights for the implementation of
preventive measures for CVEs following TAVI.
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Background: The predictors of persistent(vs transient or absent)left bundle branch block
(LBBB)after transcatheter aortic valve implantation(TAVI)with a balloon-expandable
valve(BEV)and its clinical consequences are unknown. The aim of this study was to
evaluate the predictors and prognostic value of new-onset persistent LBBB in patients
undergoing TAVI with a BEV.
Methods: A total of 202 consecutive patients with no baseline ventricular conduction
disturbances or previous permanent pacemaker implantation (PPI) who underwent TAVI
with a BEV were included. Patients were on continuous ECG monitoring during
hospitalization and 12-lead ECG was performed daily until hospital discharge. No patient
was lost at a median follow-up of 12 (6-24) months, and ECG tracing was available in
97% of patients. The criteria for PPI were limited to the occurrence of high degree
atrioventricular block (AVB) or severe symptomatic bradycardia.
Results: New-onset LBBB was observed in 61 patients (30.2%) immediately after TAVI,
and had resolved in 37.7% and 57.3 % of them at hospital discharge and at 6 to 12-months
follow-up, respectively. Baseline QRS duration (p0.037) and prosthesis ventricular
depth (p0.017) were independent predictors of persistent LBBB. Persistent LBBB at
hospital discharge was associated with a decrease in left ventricular ejection fraction
(p0.001) and poorer functional status (p0.034) at 1-year follow-up. Patients with
persistent LBBB and no PPI at hospital discharge had a higher incidence of syncope
(16.0% vs. 0.7%, p0.001) and complete AVB requiring PPI (20.0% vs. 0.7%,
p0.001), but not of global mortality, cardiac mortality or sudden death during the
follow-up period (p0.20 for all). New-onset LBBB was the only factor associated with
PPI following TAVI (p0.001).
Conclusions: Up to 30% of the patients with no prior conduction disturbances developed
new LBBB following TAVI with a BEV, although it was transient in more than one third of
them. Longer baseline QRS duration and a more ventricular positioning of the prosthesis were
associated with a higher rate of persistent LBBB, which in turn determined a higher risk for
complete AVB and PPI but not mortality or sudden death at 1-year follow-up.
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Background: A significant perivalvular aortic regurgitation (AR) is observed in 10-20%
after a successful TAVI procedure. The prognostic value and the predictors of such
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